4.8 Article

H7N9 influenza virus neutralizing antibodies that possess few somatic mutations

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 126, Issue 4, Pages 1482-1494

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI85317

Keywords

-

Funding

  1. DOE Office of Biological and Environmental Research
  2. NIH, the National Institute of General Medical Sciences (NIGMS) [P41GM103393]
  3. National Center for Research Resources (NCRR) [P41RR001209]
  4. NIH [R01 AI106002, P01AI097092, R56 AI117675, R01 GM020501, R01 AI101436]
  5. National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272200900047C, HHSN2720100007C, HHSN27220800007C]
  6. Vanderbilt NIH Clinical and Translational Science Award (CTSA) [UL1 RR024975]
  7. Department of Defense (DoD) [HDTRA1-10-1-0067]
  8. Center of Research in Influenza Pathogenesis (CRIP), an NIAID-funded Center of Excellence in Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]

Ask authors/readers for more resources

Avian H7N9 influenza viruses are group 2 influenza A viruses that have been identified as the etiologic agent for a current major outbreak that began in China in 2013 and may pose a pandemic threat. Here, we examined the human H7-reactive antibody response in 75 recipients of a monovalent inactivated A/Shanghai/02/2013 H7N9 vaccine. After 2 doses of vaccine, the majority of donors had memory B cells that secreted IgGs specific for H7 HA, with dominant responses against single HA subtypes, although frequencies of H7-reactive B cells ranged widely between donors. We isolated 12 naturally occurring mAbs with low half-maximal effective concentrations for binding, 5 of which possessed neutralizing and HA-inhibiting activities. The 5 neutralizing mAbs exhibited narrow breadth of reactivity with influenza H7 strains. Epitope-mapping studies using neutralization escape mutant analysis, deuterium exchange mass spectrometry, and x-ray crystallography revealed that these neutralizing mAbs bind near the receptor-binding pocket on HA. All 5 neutralizing mAbs possessed low numbers of somatic mutations, suggesting the clones arose from naive B cells. The most potent mAb, H7.167, was tested as a prophylactic treatment in a mouse intranasal virus challenge study, and systemic administration of the mAb markedly reduced viral lung titers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available